# Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)

> **NCT00117429** · PHASE1 · COMPLETED · sponsor: **Marcus Altfeld, M.D., Ph.D.** · enrollment: 20 (estimated)

## Conditions studied

- HIV Infections

## Interventions

- **BIOLOGICAL:** HIV gp120/NefTat/AS02A Vaccine

## Key facts

- **NCT ID:** NCT00117429
- **Lead sponsor:** Marcus Altfeld, M.D., Ph.D.
- **Sponsor class:** INDIV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2007-09
- **Final completion:** 2010-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2010-02-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117429

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117429, "Study of the HIV gp120/NefTat/AS02A Vaccine to Treat Individuals With Chronic HIV-1 Infection on Highly Active Antiretroviral Therapy (HAART)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00117429. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*